


Respiratory infections

Community acquired pneumonia: a review of common pathogens

Natalie Neu, MD

MID 2009

Respiratory tract anatomy



CAP: general principles

- Pathogenesis
- Clinical presentation
- Diagnostic work up
- Specific organisms:
 - Bacteria (e.g. *S. pneumoniae*)
 - Viral (e.g. Influenza)
 - Fungi (e.g. Histoplasma)
 - Other (e.g. Mycobacterium tuberculosis)

Community acquired pneumonia: CAP

- 5.6 million cases annually = 8-15 per 1000 persons per year
- Very young and very old usually have highest rates of disease
- Seasonal and geographic variation: WINTER!
- 3 groups for patient management
 - Outpatient, inpatient (non- intensive care unit (ICU), and ICU
- Etiology:
 - *Streptococcus pneumoniae* (#1)
 - “Atypical organisms”
 - Viral (e.g. RSV, influenza, adenovirus)
 - Gram negative
 - Other

Pathogenesis

- Lungs Defenses:
 - Innate (mucociliary escalator/phagocytes and acquired host defenses lungs-antibodies from vaccines)
- Why do you get CAP?
 - Alteration in host defenses, virulent organism or large inoculum
- How do you get CAP?
 - Micro-aspiration, hematogenous, contiguous spread, or macro-aspiration

Predisposing host conditions

- Environmental: smoking, alcoholism (altered conscienciousness), toxic inhalations, travel/geographic
- Altered lung architecture/function: cystic fibrosis, chronic obstructive lung disease (COPD), immotile cilia syndrome, Kartagener's syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)
- Altered immune system: chemotherapy, transplant, HIV, malnutrition, uremia, etc

Microbiology of CAP bacteria

- "Typical" organisms
 - *S. pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, Group A streptococci, *Moraxella catarrhalis*, anaerobes, and aerobic gram-negative bacteria.
- "Atypical" refers to pneumonia caused by *Legionella* spp, *Mycoplasma pneumoniae*, *Chlamydia* (formerly *Chlamydia pneumoniae*), and *C. psittaci*

Microbial causes of CAP in childhood

| Age | Organisms |
|--------------------|--|
| Birth to 3 weeks | Group B Streptococcal, Gram negative enteric bacilli, Cytomegalovirus, <i>Listeria monocytogenes</i> , HSV |
| 3 weeks- 3 months | <i>Chlamydia trachomatis</i> , Respiratory syncycial virus (RSV), Parainfluenza virus type 3 (PIV), <i>Streptococcus pneumoniae</i> , <i>Bordetella pertussis</i> , <i>Staphylococcus aureus</i> |
| 3 months - 5 years | RSV, PIV, influenza, adenovirus, rhinovirus, <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Mycoplasma pneumoniae</i> , <i>Mycobacterium tuberculosis</i> |
| 5-15 years | <i>Mycoplasma pneumoniae</i> , <i>Chlamydia pneumoniae</i> , <i>Streptococcus pneumoniae</i> , <i>Mycobacterium tuberculosis</i> |

IDSA/ATS Guidelines for CAP in Adults. CID 2007; 44 (suppl 2)

Table 6. Most common etiologies of community-acquired pneumonia.

| Patient type | Etiology |
|---------------------|---|
| Outpatient | <i>Streptococcus pneumoniae</i> <i>Mycoplasma pneumoniae</i> <i>Haemophilus influenzae</i> <i>Chlamydomphila pneumoniae</i> Respiratory viruses ^a |
| Inpatient (non-ICU) | <i>S. pneumoniae</i> <i>M. pneumoniae</i> <i>C. pneumoniae</i> <i>H. influenzae</i> <i>Legionella</i> species Aspiration Respiratory viruses ^a |
| Inpatient (ICU) | <i>S. pneumoniae</i> <i>Staphylococcus aureus</i> <i>Legionella</i> species Gram-negative bacilli <i>H. influenzae</i> |

NOTE. Based on collective data from recent studies [171]. ICU, intensive care unit.

^a Influenza A and B, adenovirus, respiratory syncytial virus, and parainfluenza.

Table 8. Epidemiologic conditions and/or risk factors related to specific pathogens in community-acquired pneumonia.

| Condition | Commonly encountered pathogen(s) |
|--|--|
| Alcoholism | <i>Streptococcus pneumoniae</i> , oral anaerobes, <i>Klebsiella pneumoniae</i> , <i>Acinetobacter</i> species, <i>Mycobacterium tuberculosis</i> |
| COPD and/or smoking | <i>Haemophilus influenzae</i> , <i>Pseudomonas aeruginosa</i> , <i>Legionella</i> species, <i>S. pneumoniae</i> , <i>Moraxella cararrhalsis</i> , <i>Chlamydomphila pneumoniae</i> |
| Aspiration | Gram-negative enteric pathogens, oral anaerobes |
| Lung abscess | CA-MRSA, oral anaerobes, endemic fungal pneumonia, <i>M. tuberculosis</i> , atypical mycobacteria |
| Exposure to bat or bird droppings | <i>Histoplasma capsulatum</i> |
| Exposure to birds | <i>Chlamydomphila psittaci</i> (if poultry: avian influenza) |
| Exposure to rabbits | <i>Francisella tularensis</i> |
| Exposure to farm animals or parturient cats | <i>Coxiella burnetti</i> (Q fever) |
| HIV infection (early) | <i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>M. tuberculosis</i> |
| HIV infection (late) | The pathogens listed for early infection plus <i>Pneumocystis jirovecii</i> , <i>Cryptococcus</i> , <i>Histoplasma</i> , <i>Aspergillus</i> , atypical mycobacteria (especially <i>Mycobacterium kansasii</i>), <i>P. aeruginosa</i> , <i>H. influenzae</i> |
| Hotel or cruise ship stay in previous 2 weeks | <i>Legionella</i> species |
| Travel to or residence in southwestern United States | <i>Coccidioides</i> species, <i>Hantavirus</i> |
| Travel to or residence in Southeast and East Asia | <i>Burkholderia pseudomallei</i> , avian influenza, SARS |
| Influenza active in community | Influenza, <i>S. pneumoniae</i> , <i>Staphylococcus aureus</i> , <i>H. influenzae</i> |
| Cough >2 weeks with whoop or posttussive vomiting | <i>Bordetella pertussis</i> |
| Structural lung disease (e.g., bronchiectasis) | <i>Pseudomonas aeruginosa</i> , <i>Burkholderia cepacia</i> , <i>S. aureus</i> |
| Injection drug use | <i>S. aureus</i> , anaerobes, <i>M. tuberculosis</i> , <i>S. pneumoniae</i> |
| Endobronchial obstruction | Anaerobes, <i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>S. aureus</i> |
| In context of bioterrorism | <i>Bacillus anthracis</i> (anthrax), <i>Yersinia pestis</i> (plague), <i>Francisella tularensis</i> (tularemia) |

NOTE. CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; COPD, chronic obstructive pulmonary disease; SARS, severe acute respiratory syndrome.

Pneumonia: presentation and working up the etiology

- Common complaints
 - Dyspnea, fever, cough (productive or not), chills, chest pain, myalgia, headache
- History
 - Age, co-morbidities, sick contacts, unusual exposures, social situation/support
- Physical exam findings
 - Oxygen saturation
 - Rales, tactile fremitus, decreased breath sounds, rhonchi
- Radiology
 - Confirming the diagnosis; may or may not help narrow the diagnosis e.g. *S. pneumoniae*: lobar; *S. aureus*: multilobar/abscess; Mycoplasma- diffuse interstitial

Clinical scenario 1


- Francisco is a 2 year old, previously well
- Presented with URI symptoms and fever to PMD in July
- Respiratory symptoms worsened, cxr revealed right sided pneumonia, WBC 24K with 80% PMN and 3% bands
- Initially treated with IV therapy without resolution in 4 days
- CT scan showed large right sided effusion



Complicated pneumonia with empyema

10. Ratio: 8.0. Zoom: 119%





Streptococcus pneumoniae

- Gram-positive; oval or lancet-shaped, occur in pairs or short chains (diplococci)
- Capsular polysaccharide is most important virulence factor; approximately 90 capsular types
 - Most common serotypes are 6, 14, 18, 19, and 23
- Organism causes pneumonia, meningitis, otitis media, sinusitis, bacteremia, pericarditis, arthritis

From colonization to disease

- Adherence- cell wall proteins (phosphorylcholine) allow for adherence to receptor for platelet activating factor. Other binding sites include sialic acid and N-acetylgalactosamine b1-4 galactose
 - Facilitated by viral infections
- Secretory **IgA protease** - inhibits function of secretory IgA which normally binds bacteria to mucin to facilitate clearance from the respiratory tract
- Capsule- antiphagocytic
- Invasion-cell wall, adhesins, and the cytotoxin pneumolysin- promotes intra-alveolar replication, penetration of pneumococci from the alveoli into the interstitium, and dissemination of the organisms into the bloodstream and cell death
- Host inflammatory response- cell wall (lipoteichoic acid) initiates alternative complement pathway, induce production of cytokines, nitric oxide (tissue damage), and PAF and initiate influx of neutrophils

Risk factors for pneumococcal pneumonia

- Alcohol, smoking, and asthma
- Hyposplenism or splenectomy
- Immunocompromised (HIV, chemotherapy, etc)
- Others

Risk factors resistance to β -lactam antibiotics

- Age >65
- Recently taking antibiotics within 3 months
- Alcoholism
- Immune suppression
- Multiple medical co-morbidities
- Exposure to child in daycare

S. pneumoniae

- Diagnosis
 - Blood culture
 - (6-10% CAPs are bacteremia and 60% of these are *S. pneumoniae*)
 - Urine antigen test
 - Sputum culture
- Antimicrobial susceptibility testing is key especially
 - Penicillin: 60% susceptible, 20% intermediate, 20% resistant

S. Pneumoniae


treatment and prevention

- Treatment: Beta-lactam antibiotics
 - PCN Resistance classified by breakpoints
 - Meningitis (only a fraction of plasma concentration gets in to CSF):
 - Sensitive MIC ≤ 0.6
 - Intermediate MIC 0.1-1 mcg/ml
 - Resistant MIC ≥ 2 mcg/ml
 - Non-meningitis pneumococcal disease
 - Susceptible — MIC ≤ 2 mcg/mL
 - Intermediate — MIC =4 mcg/mL
 - Resistant — MIC ≥ 8 mcg/mL
 - Cephalosporins, vancomycin, macrolides, linezolid
- Prevention: Vaccines
 - Conjugated pneumococcal vaccine (Pneumovax[®])
 - 23 valent pneumococcal vaccine (Pneumovax[®])

Clinical scenario 2

- Myra is a 21 year old medical student living in the dorm room studying for exams
- She goes to student health complaining of low grade fever, headache, non-productive cough, sore throat and general malaise
- Her exam reveals mild fine inspiratory rales- nothing impressive
- The Dr sends her for an xray that reveals bilateral infiltrates

Mycoplasma pneumonia



Mycoplasma

- Does not have a cell wall
- Cell membrane contains sterols not present in other bacteria
- Special enriched media needed for growth
- Laboratory cultures rarely done- diagnosis usually by serology (IgG)
- PCR testing not routinely available
- Bedside test- cold agglutinins

Mycoplasma- pathogenesis and immunity

- Toll-like receptor 2 important for binding to respiratory epithelium
- P1- protein attachment factor- facilitates attachment to sialic acid receptors of respiratory epithelium and RBC surface
- Remains extracellular
- Causes local destruction of cilia, interferes with normal airway clearance which leads to mechanical irritation and persistent cough
- Acts as a super antigen stimulating PMS's and macrophages to release cytokines (TNF α , IL1, and IL 6)

A common atypical pneumoia “Walking pneumonia”

- Lacks seasonal pattern, spread by droplet secretions
- Common in children and young adults
 - 7-20% of CAP especially for non-hospitalized cases
- Mild respiratory symptoms
- Complications: otitis media, erythema multiforme, hemolytic anemia, myocarditis, pericarditis, neurologic abnormalities
- Treatment: macrolides (erythromycin, azithromycin, clarithromycin) or fluoroquinolones (levofloxacin)

Erythema multiforme



Clinical scenario 3

- JM 10 week old infant born to a 16 year old mom
- Pregnancy history limited due to lack of prenatal care but baby born full term, no complications, left hospital 2 days
- Seen by pediatrician at 2 weeks old with eye discharge was given eye drops
- Returned to ER: RR 60, cough but no fever
- Xray done and bloods drawn

C. trachomatis xray



Chlamydophila (Chlamydial) pneumonias: *trachomatis*, *pneumoniae*, *psittaci*

- Intracellular parasites- use host high energy phosphate compounds
- Trilaminar outer membrane which contains LPS
- Two phase life cycle- Elementary body (infectious) and reticulate body (divides by binary fission in the host)

Chlamydophila pneumonias

- Infect non-ciliated columnar cells
- Multiply in alveolar macrophages
- Perivascular and peribronchiolar infiltrates
- Clinical symptoms due to host immune response
- Immunity not long-lasting
- Diagnosis by serology- four fold rise in titer

C. trachomatis pneumonia

- Neonatal infection presents at 1-3 months of age
- Staccato-like cough, rapid respiratory rate
- NO FEVER
- Evaluation: minimal chest findings, xray hyperinflation and diffuse infiltrates, peripheral eosinophilia
- Treatment: erythromycin
- Prevention: maternal screening

C. pneumoniae

- Single strain- TWAR
- Prolong incubation period
- Common in school age children and elderly (over 65)
- Indolent course-sore throat, chronic cough, no fever
- Chest xray variable (lobar, diffuse, bilateral)
- Diagnosis: PCR and serology
- Treatment: macrolide, doxycycline, levofloxacin

C. psittaci


- History: Parrot exposure
- Mild clinical respiratory symptoms, fever, rash
- Concomitant symptoms: cns- headache, confusion, cranial nerve palsy, seizures; hepatitis; pericarditis
- Xray-consolidation, reticular nodular pattern, adenopathy
- Titers: > 1:64 diagnostic
- Treatment: doxy, tetracycline, erythromycin

Psittacosis




Clinical scenario 4

- Charlie is a 68 year old retired plumber who recently underwent a renal transplantation
- Felt great and was tinkering around his house updating his bathroom fixtures
- Came for follow up visit complaining of high fever, cough, chills and his wife said that he was acting confused at times
- Laboratory studies reveal WBC 35,000 with left shift, LDH >1000
- Chest xray reveals multilobar process



Legionella species



The 1976 Legionnaire's Convention, Philadelphia, PA

- 29/180 patients died due to pneumonia
- Identification of a gram negative bacilli
- Epidemiologic link to being in the lobby of Hotel A; historical link to 1966 outbreak in a psychiatric hospital
- National panic- worries about biologic and chemical warfare- media frenzy
- 6 months to identify the organism

Legionella pneumophila and micdadei

- 2-6% community acquired pneumonias
- Risk: immunocompromised, hospitalized, and outbreak situations
- Gram negative bacilli- don't stain with common reagents
- 50 species and 70 serogroups- most common *L. pneumophila* and most common serogroups 1,4, 6
- Fastidious and grow on supplemented media
- Organisms contaminate water sources: air conditioning systems and water tanks

Legionella: pathogenesis and immunity

- Aspiration or inhalation of organism
- Flagellae and pili allow attachment to respiratory epithelium and macrophages
- Trafficking within cell due to dot (defective organelle trafficking) and icm (intracellular multiplication) genes which allow the organism to evade phagosome-lysosome fusion
- Intracellular replication facilitated by intracellular multiplication locus (Lgn-1) and by Mip
- Virulence factors: exotoxins, including a hemolysin, cytotoxin, deoxyribonuclease, ribonuclease, and various proteases cause destruction by killing the infected respiratory cells leading to formation of microabscesses
- Immunity primarily cell mediated immunity (T cells) (inhibited by glucocorticoids and immune suppressive agents e.g. transplant medications)

Legionnaires disease

- Incubation period up to 10 days
- Clinical- influenza like illness or severe manifestation= pneumonia
- Fever (105), rigors, cough, headache
- Multilobular infiltrates and microabscesses
- Extrapulmonary manifestations: CNS, diarrhea, abdominal pain, nausea
- High white counts, abnormal liver, renal panel
- High mortality-15-20% depending on host


Legionella: Diagnosis, prevention and treatment

- Urine antigen detection assays- EIA for *L. pneumophila* only
- Serology >1:128 positive however late development of antibodies
- Culture on special media
- Treatment: macrolide or levofloxacin
- Prevention: hyperchlorination, super heating, continuous copper-silver ionization

Clinical scenario 5 (Loyola Univ Medical Center)

- Jerry, a 7 month old child, comes to clinic with a running nose, sneezing and slightly irritable
- Diagnosed with URI
- Returns 2 weeks later because he is turning blue with coughing spells. Spells are worse at night, seems to have spasms and then he “whoops” for air.
- Examination reveals mildly dehydrated, not distressed, clear lung exam
- WBC reveals leucocytosis with lymphocytosis


Bordetella pertussis



Pertussis

- Affects children under 1 and adults with waning immunity
- Three stages of disease:
 - Catarrhal
 - Paroxysmal
 - Convalescent


Pertussis clinical symptoms




Bordetella pertussis “Whooping cough”

- Fastidious, gram negative coccobacilli
- *Pertussis, parapertussis, and bronchiseptica*
- Spread by respiratory droplets
- Rapid multiplication in mucus membrane
- No bacteremia
- Toxins cause local tissue damage


Binding and uptake by phagocytic cells



Pertussis toxin




G protein and ADP ribosylation



Toxin production and pathophysiology


| | |
|---------------------------------------|--|
| Pertussis toxin- ↑ CAMP | ↑ secretions (paroxysmal stage) |
| Adenylate cyclase and hemolysin toxin | Inhibit WBC chemotaxis, phagocytosis, and killing |
| Heat-labile toxin | Local tissue destruction |
| Tracheal cytotoxin | Destroys ciliated cells, IL-1 (fever), NO (kills epithelial cells) |
| Lipid A and Lipid X | Activate alternative complement, cytokine release |



Pertussis: diagnosis, Rx and prevention

- **Diagnosis:**
 - Special media- Bordet-Gengou- blood, charcoal, and starch. Nasopharyngeal culture
 - Serologic testing: acute and convalescent titers
 - PCR testing
- **Treatment- decrease symptoms and transmission- best if early in disease**
 - Erythromycin or Macrolide (better tolerated, shorter course)
 - Alternative for some: trimethoprim-sulfamethoxazole
- **Prevention**
 - Antimicrobial prophylaxis- close contacts and high risk individuals
 - Vaccination- during childhood and booster vaccine for those over 18 (Tdap)


FIGURE 1. Number of reported pertussis cases, by year — United States, 1922–2000



Summary: Community acquired pneumonia CAP

- Understand historical elements, physical examination finding and exposures relative for CAP
- Inpatient or outpatient management
 - Perform diagnostic tests
- Empirical antimicrobial therapy
- Prevention: smoking cessation, vaccination, etc

© Original Artist
Reproduction rights obtainable from
www.CartoonStock.com



* THE BAD NEWS IS, THERE IS NO CURE
FOR THE COMMON COLD. THE GOOD
NEWS IS, I THINK YOU HAVE PNEUMONIA. *